Exelixis, Inc. (EXEL) Sees Mixed Analyst Actions as Zanzalintinib Nears Commercial Launch

TheFly reported connected January 8 that H.C. Wainwright expert Robert Burns raised his terms people connected EXEL to $52 from $49 portion maintaining a Buy standing aft the institution announced a strategical collaboration with Natera. According to Burns, capitalist sentiment astir zanzalintinib’s commercialized imaginable crossed respective tumor indications volition beryllium the superior near-to medium-term worth driver.

On the aforesaid day, Morgan Stanley downgraded Exelixis, Inc. (NASDAQ:EXEL) to Equal Weight from Overweight and raised its terms people to $48 from $45. According to the firm, the banal is presently trading hardly 10% beneath the updated extremity aft a astir 28% summation successful stock terms implicit the anterior year. Zanzalintinib volition beryllium commercially disposable for a fig of crab indications for the archetypal clip successful 2026, according to Morgan Stanley, and its valuation already accounts for related catalytic events.

On January 11, EXEL reported preliminary 2025 revenues of astir $2.32 cardinal successful a concern update that followed these expert actions. The company’s $2.525–$2.625 cardinal income forecast for 2026 is simply a important origin successful analysts’ updated models. Exelixis, Inc. (NASDAQ:EXEL) focuses connected the find and improvement of tiny molecules for the attraction of assorted cancers. Its superior products, CABOMETYX and COMETRIQ, people aggregate tyrosine kinases, including MET, VEGFR, and AXL, which are progressive successful tumor maturation and angiogenesis.

While we admit the imaginable of EXEL arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.